Geron Corporation (GERN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $622.98M
Last updated: Nov 17, 2026 at 11:06 AM ET
Geron Corporation (GERN) Financials: Revenue, Profit and Cash Flow
Geron reported revenue of $183.88M for the fiscal year ended Dec 31, 2025, up 138.8% from the year before. That year, net income was -$83.50M with a net margin of -45.4%, operating cash flow was -$111.04M and free cash flow was -$111.09M. The quarter ended Sep 30, 2026 had revenue of $60.19M and net income of $1.35M.
Revenue and Margins
The operating margin was -37.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $6.16M, a compound annual rate of 45.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $183.88M | +138.8% | 97.4% | -37.3% | -45.4% |
| Dec 2024 | $76.99M | N/A | 98.4% | -225.6% | -226.7% |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2021 | $1.39M | +450.6% | 100.0% | -8183.7% | -8335.4% |
| Dec 2020 | $253.00K | -45.0% | 100.0% | -30400.4% | -29888.1% |
| Dec 2019 | $460.00K | -56.8% | 100.0% | -15762.0% | -14901.7% |
| Dec 2018 | $1.07M | +0.1% | 100.0% | -2914.9% | -2534.4% |
| Dec 2017 | $1.06M | -82.7% | 100.0% | -2746.9% | -2621.2% |
| Dec 2016 | $6.16M | N/A | 100.0% | -497.3% | -479.3% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $183.88M | $76.99M | $0 | $0 | $1.39M | $253.00K | $460.00K | $1.07M | $1.06M | $6.16M |
| Cost of revenue | $4.75M | $1.26M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $179.14M | $75.74M | $0 | $0 | $1.39M | $253.00K | $460.00K | $1.07M | $1.06M | $6.16M |
| Research and development | $71.43M | $103.74M | $125.05M | $95.52M | $85.73M | $51.49M | $52.07M | $13.43M | $11.03M | $18.05M |
| Operating income | -$68.58M | -$173.73M | -$193.94M | -$138.55M | -$114.00M | -$76.91M | -$72.50M | -$31.07M | -$29.25M | -$30.65M |
| Net income | -$83.50M | -$174.57M | -$184.13M | -$141.90M | -$116.11M | -$75.62M | -$68.55M | -$27.02M | -$27.92M | -$29.54M |
| EBITDA | N/A | N/A | N/A | -$136.32M | -$109.80M | -$74.75M | N/A | N/A | -$28.98M | -$30.10M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $60.19M | $57.48M | $51.84M | $48.02M | $47.23M | $49.04M | $39.60M | $47.54M | $28.27M | $882.00K | $304.00K | -$193.00K |
| Gross profit | $54.14M | $48.24M | $50.15M | $46.71M | $46.18M | $47.85M | $38.40M | $46.75M | $27.82M | $865.00K | $304.00K | -$193.00K |
| Operating income | $5.80M | -$12.50M | $158.00K | -$25.54M | -$13.89M | -$12.45M | -$16.70M | -$20.05M | -$28.21M | -$69.33M | -$56.13M | -$54.29M |
| Net income | $1.35M | -$16.68M | -$3.64M | -$28.86M | -$18.43M | -$16.38M | -$19.84M | -$25.35M | -$26.45M | -$67.38M | -$55.39M | -$51.97M |
Balance Sheet
As of Dec 2025, total debt of $139.00M exceeded cash and equivalents by $61.44M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $570.54M | $593.78M | $394.08M | $190.57M | $226.03M | $270.73M | $165.52M | $185.28M | $110.31M | $130.25M |
| Current assets | $520.27M | $490.99M | $341.35M | $180.25M | $187.21M | $199.86M | $141.61M | $166.06M | $95.97M | $116.11M |
| Cash and equivalents | $77.56M | $79.02M | $70.02M | $56.84M | $34.87M | $9.93M | $13.64M | $10.57M | $16.34M | $12.81M |
| Total liabilities | $344.67M | $313.46M | $146.13M | $110.58M | $99.62M | $59.78M | $30.36M | $7.55M | $6.52M | $7.87M |
| Short-term debt | $19.45M | $974.00K | $46.89M | $20.95M | $0 | $878.00K | $354.00K | N/A | N/A | N/A |
| Long-term debt | $119.55M | $118.48M | $35.05M | $30.21M | $49.83M | $24.04M | $0 | N/A | $0 | $0 |
| Shareholder equity | $225.87M | $280.32M | $247.95M | $80.00M | $126.42M | $210.95M | $135.16M | $177.73M | $103.80M | $122.38M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $527.11M | $519.01M | $534.12M | $570.54M | $567.38M | $555.20M | $562.45M | $593.78M | $444.95M | $449.40M | $482.07M | $394.08M |
| Total liabilities | $300.41M | $300.39M | $305.01M | $344.67M | $318.68M | $295.67M | $294.21M | $313.46M | $152.67M | $142.70M | $137.21M | $146.13M |
| Cash and equivalents | $69.18M | $62.64M | $68.89M | $79.44M | $78.12M | $77.73M | $83.75M | $79.02M | $60.34M | $116.94M | $189.76M | $71.14M |
| Shareholder equity | $226.69M | $218.61M | $229.11M | $225.87M | $248.71M | $259.53M | $268.24M | $280.32M | $292.28M | $306.69M | $344.87M | $247.95M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$111.04M | -$218.62M | -$167.74M | -$127.38M | -$95.56M | -$66.65M | -$43.83M | -$21.01M | -$20.56M | -$18.37M |
| Capital expenditures | $49.00K | $680.00K | $830.00K | $431.00K | $207.00K | $401.00K | $413.00K | $16.00K | $16.00K | $57.00K |
| Free cash flow | -$111.09M | -$219.30M | -$168.57M | -$127.81M | -$95.76M | -$67.05M | -$44.24M | -$21.02M | -$20.57M | -$18.43M |
| Investing cash flow | $107.25M | -$106.00M | -$180.32M | $62.07M | $71.95M | -$105.32M | $27.40M | -$77.72M | $22.97M | $8.76M |
| Financing cash flow | $2.27M | $334.37M | $362.02M | $87.26M | $48.56M | $168.35M | $19.50M | $92.97M | $1.11M | $1.17M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $10.27M | -$15.83M | -$62.91M | -$22.07M | -$13.58M | -$27.41M | -$47.98M | -$43.95M | -$58.94M | -$53.48M | -$62.25M | -$40.94M |
| Capital expenditures | $154.00K | $223.00K | $252.00K | $32.00K | $89.00K | $170.00K | $32.00K | $141.00K | $0 | $206.00K | $615.00K | $64.00K |
| Free cash flow | $10.11M | -$16.05M | -$63.16M | -$22.10M | -$13.66M | -$27.59M | -$48.01M | -$44.09M | -$58.94M | -$53.68M | -$62.87M | -$41.00M |
Frequently Asked Questions About GERN
What is Geron's annual revenue?
Geron reported revenue of $183.88M for the fiscal year ended Dec 31, 2025.
How fast is Geron's revenue growing?
Revenue was up 138.8% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Geron profitable?
No. Geron reported net income of -$83.50M for the fiscal year ended Dec 31, 2025, with a net margin of -45.4%.
How much free cash flow does GERN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$111.04M minus capital expenditures of $49.00K produced free cash flow of -$111.09M.
How much debt does Geron have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $119.55M, short-term debt of $19.45M and cash and equivalents of $77.56M.
GERN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors